BERKELEY, Calif. and MAINZ, Germany - Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company, today announced updates to its ColoAlert product, which is aimed at improving the screening process for colorectal cancer (CRC).
The company, which specializes in early cancer detection, has introduced a new DNA stabilizing buffer to ColoAlert, designed to handle varying sample volumes and reduce the need for retesting.
ColoAlert is a non-invasive at-home test that combines the analysis of cell DNA for specific tumor markers with the fecal immunochemical test (FIT). The updates are expected to decrease the industry's retesting rates by accommodating samples that are often underfilled or overfilled, which previously led to unsuitable samples for laboratory analysis.
With the new buffer, Mainz Biomed anticipates delivering screening results within 2-3 days after the laboratory receives the sample.
In addition to the novel buffer, ColoAlert's kit has been refined for better usability. The improvements include an enhanced collection device, a new tube and tube holder, among other features, to simplify the sample collection process for users.
Tarrin Khairi-Taraki, VP Commercial Operations at Mainz Biomed, expressed the company's dedication to optimizing testing procedures and ensuring patient convenience. The improved ColoAlert product is now available to existing laboratory partners and new collaborators.
Colorectal cancer is the third most common cancer worldwide, with over 1.9 million new cases in 2020, as reported by the World Cancer Research Fund International. In the US alone, there is a significant market opportunity, with a third of residents aged 50-75 having never been screened for colon cancer.
Mainz Biomed is known for developing diagnostic solutions for life-threatening conditions. Their flagship product, ColoAlert, is already marketed across Europe, and the company plans to pursue FDA approval in the United States. Mainz Biomed is also working on PancAlert, a screening test for pancreatic cancer.
In other recent news, Mainz Biomed has made significant strides in its clinical studies, particularly in the early detection of colorectal cancer (CRC). The company's ColoAlert® test, currently under scrutiny for FDA approval, has shown promising results in recent studies, demonstrating a 92% sensitivity for CRC and 82% for advanced adenomas.
The company's findings were recognized at the American Society of Clinical Oncology and Digestive Disease Week, further solidifying its credibility in the field.
Jones Trading, despite halving its stock price target for Mainz Biomed due to financial concerns, maintains a Buy rating for the company. The firm sees potential in ColoAlert, which is expected to debut in the U.S. market in the first quarter of 2027.
In addition, Mainz Biomed is set to commence enrollment for the ReconAAsense U.S. FDA pivotal CRC study later this year.
Strategic partnerships with organizations like Trusted Health Advisors in the U.S. and TomaLab in Italy are also part of Mainz Biomed's recent developments. These collaborations aim to gain market approval and integrate ColoAlert® into healthcare systems.
InvestingPro Insights
Mainz Biomed N.V. (NASDAQ:MYNZ), with its focus on enhancing the screening process for colorectal cancer through its ColoAlert product, has shown a dedication to innovation in the molecular genetics diagnostic field. However, a look at the company's financial health through InvestingPro data reveals a challenging landscape. The market capitalization of Mainz Biomed stands at a modest $7.88 million, reflecting its status as a small-cap company in the biotech sector. The company's revenue for the last twelve months as of Q4 2023 was $0.9 million, with a notable revenue growth of 69.0%, indicating potential in its market niche despite its size.
Yet, the company's financial metrics suggest that profitability remains a concern, with a negative P/E ratio of -0.28 and an adjusted P/E ratio for the same period at -0.29. Additionally, Mainz Biomed's operating income margin for the last twelve months as of Q4 2023 was deeply negative at -2975.47%, underscoring the significant expenses incurred beyond its gross profits. These figures are in line with the InvestingPro Tips, which highlight that analysts do not anticipate the company will be profitable this year and that Mainz Biomed is quickly burning through cash.
The company's stock price has also taken a significant hit, with a 1-year price total return of -91.98% as of mid-2024. This sharp decline is reflected in the stock price being only 7.64% of its 52-week high, which may concern potential investors about the stock's volatility.
InvestingPro offers additional insights into Mainz Biomed, with a total of 9 InvestingPro Tips available for investors who are looking to dive deeper into the company's financials and market performance. These include observations on the company's debt levels, cash flow yield, and dividend policy, among others. For readers interested in accessing these valuable tips, they can visit https://www.investing.com/pro/MYNZ and use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
Despite the financial challenges indicated by the data, Mainz Biomed's commitment to improving early cancer detection and expanding its product offerings like PancAlert could pave the way for future growth and market penetration, particularly if the company secures FDA approval for its products in the lucrative U.S. market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.